On December 31, 2021, Charles H. Randall, chief strategy officer of SAB Biotherapeutics, Inc. resigned. The company and Mr. Randall are finalizing the terms of a release and severance under his employment agreement.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.67 USD | +1.14% | -1.84% | -61.16% |
05-30 | SAB Biotherapeutics, Inc. Announces Change of Chief Financial Officer | CI |
05-21 | FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-61.16% | 24.36M | |
+15.55% | 118B | |
+12.66% | 106B | |
-2.53% | 24.28B | |
+1.14% | 21.96B | |
-9.35% | 18.16B | |
-42.28% | 16.37B | |
-18.92% | 15.56B | |
+6.19% | 13.63B | |
+28.83% | 12.27B |
- Stock Market
- Equities
- SABS Stock
- News SAB Biotherapeutics, Inc.
- SAB Biotherapeutics, Inc. Announces Resignation of Charles H. Randall as Chief Strategy Officer